Pharmaceutical Technology on MSN
Novartis wins FDA approval for Cosentyx to treat paediatric HS patients
Cosentyx’s IL-17A mechanism provides a differentiated approach for HS in younger patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results